LamImSys Lab, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria (UFV), 28223 Madrid, Spain.
Int J Mol Sci. 2021 Jul 16;22(14):7618. doi: 10.3390/ijms22147618.
Inflammatory bowel disease (IBD) is a heterogeneous state of chronic intestinal inflammation of unknown cause encompassing Crohn's disease (CD) and ulcerative colitis (UC). IBD has been linked to genetic and environmental factors, microbiota dysbiosis, exacerbated innate and adaptive immunity and epithelial intestinal barrier dysfunction. IBD is classically associated with gut accumulation of proinflammatory Th1 and Th17 cells accompanied by insufficient Treg numbers and Tr1 immune suppression. Inflammatory T cells guide innate cells to perpetuate a constant hypersensitivity to microbial antigens, tissue injury and chronic intestinal inflammation. Recent studies of intestinal mucosal homeostasis and IBD suggest involvement of innate lymphoid cells (ILCs). These lymphoid-origin cells are innate counterparts of T cells but lack the antigen receptors expressed on B and T cells. ILCs play important roles in the first line of antimicrobial defense and contribute to organ development, tissue protection and regeneration, and mucosal homeostasis by maintaining the balance between antipathogen immunity and commensal tolerance. Intestinal homeostasis requires strict regulation of the quantity and activity of local ILC subpopulations. Recent studies demonstrated that changes to ILCs during IBD contribute to disease development. A better understanding of ILC behavior in gastrointestinal homeostasis and inflammation will provide valuable insights into new approaches to IBD treatment. This review summarizes recent research into ILCs in intestinal homeostasis and the latest advances in the understanding of the role of ILCs in IBD, with particular emphasis on the interaction between microbiota and ILC populations and functions.
炎症性肠病(IBD)是一种慢性肠道炎症的异质性状态,其病因不明,包括克罗恩病(CD)和溃疡性结肠炎(UC)。IBD 与遗传和环境因素、微生物群落失调、先天和适应性免疫增强以及上皮肠道屏障功能障碍有关。IBD 通常与肠道中促炎 Th1 和 Th17 细胞的积累有关,同时伴随着 Treg 数量不足和 Tr1 免疫抑制。炎症性 T 细胞引导先天细胞持续对微生物抗原、组织损伤和慢性肠道炎症产生过敏反应。最近对肠道黏膜稳态和 IBD 的研究表明,固有淋巴细胞(ILCs)的参与。这些淋巴细胞起源的细胞是 T 细胞的先天对应物,但缺乏 B 和 T 细胞上表达的抗原受体。ILCs 在抗菌防御的第一线发挥重要作用,并通过维持抗病原体免疫和共生耐受之间的平衡,为器官发育、组织保护和再生以及黏膜稳态做出贡献。肠道稳态需要严格调节局部 ILC 亚群的数量和活性。最近的研究表明,IBD 期间 ILCs 的变化有助于疾病的发展。更好地了解 ILC 在胃肠道稳态和炎症中的行为将为 IBD 的治疗提供有价值的见解。本综述总结了最近关于 ILC 在肠道稳态中的研究进展,以及对 ILC 在 IBD 中作用的最新认识,特别强调了微生物群和 ILC 群体及其功能之间的相互作用。